Supernus Pharmaceuticals SUPN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $207.71M-1.8% | $211.57M+10.1% | $192.1M+16.1% | $165.45M+10.4% | $149.82M-14.0% | ||
| $23.39M+1.7% | $23.01M+21.3% | $18.97M+12.7% | $16.83M+6.7% | $15.76M-39.6% | ||
| $184.31M-2.3% | $188.57M+8.9% | $173.14M+16.5% | $148.63M+10.9% | $134.06M-9.5% | ||
| 88.7%-0.4pp | 89.1%-1.0pp | 90.1%+0.3pp | 89.8%+0.4pp | 89.5%+4.5pp | ||
| $39.44M+41.7% | $27.83M-5.2% | $29.37M+32.8% | $22.12M-17.9% | $26.93M-6.0% | ||
| $125.17M+2.3% | $122.39M-31.9% | $179.68M+92.1% | $93.55M+4.0% | $89.94M+13.3% | ||
| $216.04M+0.2% | $215.51M-14.6% | $252.33M+64.6% | $153.31M-4.2% | $160.08M+4.8% | ||
| -$8.33M-112% | -$3.94M+93.5% | -$60.23M-596% | $12.14M+218% | -$10.26M-148% | ||
| -4%-2.2pp | -1.9%+29.5pp | -31.4%-38.7pp | 7.3%+14.2pp | -6.8%-19.1pp | ||
| $2.38M+17.7% | $2.02M-11.2% | $2.28M-49.7% | $4.53M+2.3% | $4.43M-11.1% | ||
| -$5.95M-211% | -$1.91M+96.7% | -$57.95M-448% | $16.67M+386% | -$5.83M-122% | ||
| -$3.66M— | —— | -$12.84M-120% | -$5.83M-197% | $6M-45.8% | ||
| -$2.29M+44.1% | -$4.11M+90.9% | -$45.12M-301% | $22.5M+290% | -$11.83M-177% | ||
| -1.1%+0.8pp | -1.9%+21.5pp | -23.5%-37.1pp | 13.6%+21.5pp | -7.9%-16.7pp | ||
| -$0.04+42.9% | -$0.07+91.3% | -$0.80-300% | $0.40+290% | -$0.21-178% | ||
| $17.8M-15.6% | $21.08M+160% | -$35.43M-206% | $33.5M+231% | $10.13M-74.8% | ||
| 8.6%-1.4pp | 10%+28.4pp | -18.4%-38.7pp | 20.2%+13.5pp | 6.8%-16.4pp | ||
| -$8.33M-112% | -$3.94M+93.5% | -$60.23M-596% | $12.14M+218% | -$10.26M-148% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Supernus Pharmaceuticals's revenue?
- Supernus Pharmaceuticals (SUPN) generated $776.8M in revenue over the trailing twelve months, up 16.3% year over year.
- Is Supernus Pharmaceuticals profitable?
- Supernus Pharmaceuticals is not currently profitable: it reported a net loss of $29.0M over the trailing twelve months, a -3.7% net margin.
- What are Supernus Pharmaceuticals's profit margins?
- Gross margin is 89.4% and operating margin is -7.8%, with a -3.7% net margin.
- What is Supernus Pharmaceuticals's earnings per share?
- Supernus Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.51.
- Where does Supernus Pharmaceuticals's income statement data come from?
- Every line is extracted from Supernus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
